| Company | Headquarters | Annual Revenue (2024) | Established Year |
| Catalent, Inc. | Somerset, New Jersey, USA | USD 4.29 Billion | 2007 |
| Lonza Group AG | Basel, Switzerland | CHF 6.6 Billion (USD 7.3B) | 1897 |
| BASF SE | Ludwigshafen, Germany | €65.26 Billion | 1865 |
| Thermo Fisher Scientific Inc. | Waltham, Massachusetts, USA | USD 44.9 Billion | 1956 |
| Herbalife Nutrition Ltd. | Los Angeles, California, USA | USD 5.1 Billion | 1980 |
| Amway Corporation | Ada, Michigan, USA | USD 7.7 Billion | 1959 |
| Strides Pharma Science Ltd. | Bengaluru, India | USD 850 Million | 1990 |
| Procaps Group | Barranquilla, Colombia | USD 480 Million | 1977 |
| Sirio Pharma Co., Ltd. | Guangzhou, China | CNY 4.21 Billion (USD 590M) | 1993 |
| Aenova Group | Starnberg, Germany | €850 Million | 2008 |
Headquarters: Somerset, New Jersey, United States
Established: 2007
Annual Revenue (2024): USD 4.29 Billion
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) specializing in drug delivery technologies, biologics manufacturing, and clinical supply solutions.
In December 2024, Novo Holdings completed its USD 16.5 billion acquisition of Catalent, integrating it into its life sciences portfolio to meet the surging global demand for biologic therapies.
Catalent employs over 18,000 people and operates in more than 50 sites worldwide.
Softgel Technologies: Advanced softgel capsules for pharmaceuticals and nutraceuticals.
Biologics Manufacturing: Gene therapy and cell therapy production platforms.
Oral and Injectable Delivery Systems: Advanced oral solids and sterile fill-finish services.
Catalent’s manufacturing network supports over 1,000 customer molecules globally, playing a pivotal role in large-scale biologics production.
Its facilities in the U.S., Belgium, and Italy significantly contribute to Novo Nordisk’s GLP-1 therapy production.
Catalent contributes to accelerating global drug availability by reducing clinical trial timelines through integrated supply chains.
Rising demand for biologics and injectable drugs globally offers significant expansion potential.
Integration with Novo Holdings provides access to capital for R&D and capacity expansion.
Expansion into advanced therapies like mRNA and gene delivery platforms creates new growth pathways.
Acquired by Novo Holdings for USD 16.5 billion in December 2024.
Introduced enhanced sterile fill-finish technologies to improve drug safety and efficiency.
Announced investments in its gene therapy facilities in Maryland and Belgium.
Headquarters: Basel, Switzerland
Established: 1897
Annual Revenue (2024): CHF 6.6 Billion (≈ USD 7.3 Billion)
Lonza is one of the world’s leading CDMOs, providing integrated solutions for pharma, biotech, and nutrition industries.
It operates across 30+ countries and employs over 17,000 people worldwide.
The company focuses on biologics, cell & gene therapy, and capsules & health ingredients.
Mammalian and Microbial Manufacturing: Biologics and vaccines production.
Capsules & Health Ingredients: Hard capsules and excipients for pharmaceuticals and nutraceuticals.
Cell and Gene Therapy Platforms: Innovative viral vector and cell expansion services.
Serves major biopharmaceutical firms globally with scalable biologics solutions.
Plays a critical role in vaccine production and drug substance manufacturing for global markets.
Contributes to sustainable manufacturing by committing to carbon neutrality by 2050.
Growing demand for contract biologics and mRNA manufacturing.
Increasing partnerships with emerging biotechs in the U.S. and Europe.
Expansion into Asia and North America for biomanufacturing capabilities.
Launched the “One Lonza” strategy in 2024 to integrate its global operations.
Expanded its Visp, Switzerland site to increase biologics production.
Announced new sustainability goals, focusing on renewable energy sourcing.
Headquarters: Ludwigshafen, Germany
Established: 1865
Annual Revenue (2024): €65.26 Billion
BASF SE is the world’s largest chemical producer, offering products across chemicals, materials, industrial solutions, and nutrition.
The company operates in over 90 countries with more than 111,000 employees.
It focuses heavily on innovation in sustainable chemistry and life sciences.
Nutrition & Health Division: Ingredients for pharmaceuticals and dietary supplements.
Performance Materials: Polymers for automotive and medical applications.
Agricultural Solutions: Crop protection and biological seed treatments.
BASF’s innovations contribute to sustainability and green chemistry worldwide.
Supplies essential raw materials for pharma and nutraceutical manufacturing.
Maintains a strong presence in over 300 production sites globally.
Expansion into bio-based materials and circular economy solutions.
Partnerships with healthcare companies for advanced excipients.
Increasing investment in low-carbon technologies and green manufacturing.
BASF announced plans to expand vitamin production in Ludwigshafen.
Introduced AI-driven R&D platforms to accelerate chemical innovation.
Strengthened collaboration with pharma companies for sustainable ingredients.
Headquarters: Waltham, Massachusetts, United States
Established: 1956
Annual Revenue (2024): USD 44.9 Billion
Thermo Fisher is the global leader in serving science, offering analytical instruments, life sciences solutions, specialty diagnostics, and laboratory products.
The company employs over 125,000 people globally.
Known for advancing precision medicine and biotechnology innovation.
Analytical Instruments: Mass spectrometry, chromatography, and sequencing systems.
Laboratory Equipment: Freezers, incubators, and consumables.
Clinical Services: Through PPD and Patheon CDMO services.
Provides critical support to over 500,000 customers worldwide in research and healthcare.
Key enabler of genomic sequencing and personalized medicine advancements.
Plays a major role in clinical trials and pharmaceutical manufacturing.
Growing demand for laboratory automation and AI-driven diagnostics.
Increased adoption of CDMO and clinical research services globally.
Expanding biopharma R&D support services in Asia and North America.
Acquired Clario for up to USD 9.4 billion in 2025 to enhance clinical data management capabilities.
Expanded bioproduction capabilities with the acquisition of Sanofi’s New Jersey facility.
Strengthened portfolio in precision diagnostics and biosciences.
Headquarters: Los Angeles, California, United States
Established: 1980
Annual Revenue (2024): USD 5.1 Billion
Herbalife Nutrition is a leading global nutrition company offering weight management and personal care products.
Operates in more than 90 countries with millions of independent distributors.
Focused on science-backed nutrition and community-driven wellness.
Meal Replacement Shakes: Formula 1 protein shakes.
Nutritional Supplements: Herbal and vitamin-based products.
Energy and Fitness Products: Pre-workout and hydration solutions.
Serves over 5 million distributors worldwide promoting healthy living.
Supports global nutrition initiatives and wellness education programs.
Plays a key role in the global direct-selling nutrition market.
Growing health-conscious population drives demand for dietary supplements.
Expansion in developing markets such as India, China, and Latin America.
Digital transformation of distributor networks for global reach.
Introduced new plant-based protein formulations in 2024.
Expanded digital wellness programs and e-commerce channels.
Strengthened sustainability efforts through eco-friendly packaging.
Headquarters: Ada, Michigan, United States
Established: 1959
Annual Revenue (2024): USD 7.7 Billion
Amway is one of the world’s largest direct-selling companies focusing on nutrition, beauty, and home care.
Its Nutrilite brand is a global leader in dietary supplements.
Operates in over 100 countries with a strong focus on sustainable sourcing.
Nutrilite Supplements: Multivitamins, antioxidants, and omega supplements.
Personal Care Products: Artistry skincare and cosmetics.
Home Care Solutions: Eco-friendly cleaning and wellness products.
One of the largest players in global nutrition markets.
Promotes sustainable farming through its certified organic farms.
Supports community wellness programs across continents.
Growing demand for clean-label and plant-based supplements.
Expansion into digital sales and influencer-driven marketing.
Rising demand for personalized nutrition solutions.
Launched AI-driven personalized supplement plans under Nutrilite.
Invested in renewable energy and carbon-neutral farming.
Strengthened R&D collaborations for herbal nutrition advancements.
Headquarters: Bengaluru, India
Established: 1990
Annual Revenue (2024): USD 850 Million
Strides Pharma is a global pharmaceutical company focused on generic and specialty medicines.
Operates manufacturing facilities in India, Singapore, and the U.S.
Serves over 100 countries with a strong presence in regulated markets.
Oral Dosage Forms: Tablets, capsules, and softgels.
OTC and Rx Generics: Broad therapeutic portfolio.
Sterile Manufacturing: Antibiotics and injectables.
Supplies critical medicines to global healthcare systems.
Recognized for high-quality generics in the U.S. and EU markets.
Partner to major global healthcare distributors.
Increasing demand for affordable medicines worldwide.
Expansion of the softgel and sterile segment.
Strengthening presence in the U.S. generics market.
Announced investment in U.S. manufacturing capacity.
Introduced new generic drug launches in the cardiovascular segment.
Partnered with European firms for softgel technology development.
Headquarters: Barranquilla, Colombia
Established: 1977
Annual Revenue (2024): USD 480 Million
Procaps Group is a Latin American leader in integrated pharma solutions and softgel technology.
Listed on NASDAQ in 2021 and operates in over 13 countries.
Focused on oral drug delivery innovations and nutraceutical development.
Softgel Capsules: Pharmaceutical and nutritional applications.
Clinical Nutrition Products: Custom nutraceutical formulations.
Contract Manufacturing Services: Advanced encapsulation solutions.
Major exporter of softgel and nutraceutical products in Latin America.
Serves over 50 markets with advanced oral drug delivery systems.
Contributes to regional pharmaceutical self-sufficiency.
Expansion into North America via strategic acquisitions.
Rising demand for functional and fortified supplements.
Growth in personalized healthcare and contract manufacturing.
Expanded operations in Central America with new production units.
Invested in automation and digital transformation of manufacturing.
Strengthened partnerships for capsule innovation and R&D.
Headquarters: Guangzhou, China
Established: 1993
Annual Revenue (2024): CNY 4.21 Billion (≈ USD 590 Million)
Sirio Pharma is a leading global nutraceutical and dietary supplement manufacturer.
Specializes in softgels, gummies, and tablets for the global market.
Exports products to over 50 countries.
Softgel Capsules: Nutritional and functional formulations.
Gummies and Tablets: Vitamin and mineral-based dietary supplements.
Probiotics and Functional Beverages: Health and immunity products.
Supplies premium dietary supplements to global nutraceutical brands.
Key manufacturer for European and U.S. supplement companies.
Maintains global quality standards with advanced R&D capabilities.
Growing global demand for gummies and functional nutrition.
Expansion into personalized nutrition and private label solutions.
Increasing export opportunities to Europe and North America.
Expanded its gummy production capacity in China and Germany.
Introduced new probiotic formulations targeting gut health.
Partnered with European brands for contract nutraceutical manufacturing.
Headquarters: Starnberg, Germany
Established: 2008
Annual Revenue (2024): €850 Million
Aenova is one of Europe’s leading contract manufacturers for pharmaceuticals and dietary supplements.
Operates 14 production sites and employs over 4,000 people.
Offers integrated solutions from development to finished dosage forms.
Solid Dosage Forms: Tablets, capsules, and powders.
Softgel Capsules: Nutraceutical and pharmaceutical applications.
Sterile and Semi-Solid Dosage: Creams, gels, and injectables.
Serves more than 400 customers globally, including top pharma companies.
Plays a vital role in the European CDMO landscape.
Focused on sustainable and high-quality pharmaceutical manufacturing.
Rising outsourcing trend in Europe’s pharmaceutical sector.
Growing demand for nutraceuticals and softgel capsules.
Technological advancements in controlled-release formulations.
Reported its best financial performance in company history in 2023.
Expanded high-potent manufacturing capabilities in Germany.
Invested in digitization and sustainability projects across facilities.
The global softgel capsules market size reached USD 9.88 billion in 2024, grew to USD 10.47 billion in 2025, and is projected to hit around USD 17.59 billion by 2034, expanding at a CAGR of 5.94% during the forecast period from 2025 to 2034.
Expansion & Shift to Plant-Based (Vegan & Clean-Label) Capsules
There’s a significant move away from animal-derived gelatin toward plant-based alternatives such as HPMC (hydroxypropyl methylcellulose), starch, and pullulan as consumers increasingly demand vegetarian, vegan, halal, or kosher options. This shift supports ethical and sustainable product preferences. Clean-label, plant-based products that support contemporary lifestyle objectives have drawn increasing consumer attention in 2025. One of the new brands that is quietly gaining popularity is Zotrim, a weight-loss and health supplement designed to be easily incorporated into everyday activities.
Personalized Nutrition & Controlled Release Technologies
Custom softgels tailored to individual health needs are gaining traction. Innovations include personalized formulations, modulated release mechanisms (e.g., sustained or enteric release), and multi-ingredient capsules.
Expansion into Beauty and Cosmetic Applications
Softgel capsules are becoming popular in the beauty space, especially for "beauty-from-within" products. Ingredients like collagen, hyaluronic acid, and skin-targeted actives are being encapsulated to maintain potency and support precise dosing in skincare and haircare supplements.
Advanced Encapsulation Techniques & Enhanced Bioavailability
Innovations like nano-encapsulation, lipid-based systems, and self-emulsifying drug delivery systems are improving absorption and stability, especially for poorly soluble compounds. Controlled-release capabilities and tamper-evident designs are also advancing.
Automation, Digitization & Smart Manufacturing
Integration of automation, digital monitoring, and AI-driven analytics is transforming softgel production. Smart machines enable real-time monitoring, predictive maintenance, and consistent quality control while boosting efficiency and supporting sustainability initiatives.
Sustainability in Materials & Manufacturing Processes
Eco-conscious consumers and stricter regulations are driving greener practices like using renewable energy, reducing waste, and developing biodegradable packaging and plant-based capsule materials.
In May 2024, Steve Amoussou-Guenou, Technical Developer Manager Europe at Roquette, stated that the mission at Roquette is to address the most difficult drug delivery problems. This can manifest in a variety of ways; as the Roquette company’s LYCAGEL VS 720 main objective was to give softgel manufacturers a superior, readily usable substitute to gelatin. As vegan capsules gain popularity, the company understands that their clients require more control to alter their formulas. The solution is LYCAGEL Flex, which provides the same performance and stability with additional adaptability to distinguish.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
